Article

PRL offers good results for high myopia

Implantation of phakic refractive lenses (PRL) appears to be a predictable and well-tolerated procedure for correcting high myopia.

Implantation of phakic refractive lenses (PRL) appears to be a predictable and well-tolerated procedure for correcting high myopia, according to Esther Arranz-Marquez and co-workers from Vissum Corporación Oftalmológica de Madrid, Spain.

In a prospective study, the PRL was implanted in 78 myopic eyes in which the refractive error ranged between -4.0 and -31.0 D and laser refractive surgery was contraindicated. Uncorrected and best corrected visual acuity (UCVA & BCVA), manifest and cycloplegic refractions and intraocular pressure (IOP) were assessed over a three-year follow-up period.

The results revealed a significant change in spherical equivalent from a preoperative mean value of -14.7±5.4 D to 0±0.8 D three years postoperatively (p<0.01). UCVA and BCVA also improved significantly (p<0.01). Although a significant increase in IOP was found at each postoperative visit (p<0.01), there was no significant difference in IOP between one and three years postoperatively. Four eyes were operated on again due to mild lens decentration.

It was concluded that implantation of a PRL can offer good and predictable results for the correction of high myopia.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
© 2025 MJH Life Sciences

All rights reserved.